<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1186/s13256-019-2062-3</query><apiKey>6b19ee21fe6a243741a528650f7c8997</apiKey><result><total>1</total><start>1</start><pageLength>1</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">13256</journal-id><journal-title-group><journal-title>Journal of Medical Case Reports</journal-title><abbrev-journal-title abbrev-type="publisher">J Med Case Reports</abbrev-journal-title></journal-title-group><issn pub-type="epub">1752-1947</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s13256-019-2062-3</article-id><article-id pub-id-type="manuscript">2062</article-id><article-id pub-id-type="doi">10.1186/s13256-019-2062-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Bacteremia by colistin-resistant <italic>Acinetobacter baumannii</italic> isolate: a case report</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="Au1"><name><surname>Garcia Casallas</surname><given-names>Julio Cesar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="corresp" rid="IDs1325601920623_cor1">a</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Robayo-Amortegui</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Corredor-Rozo</surname><given-names>Z.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Carrasco-Márquez</surname><given-names>A. M.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" id="Au5"><name><surname>Escobar-Perez</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2111 4451</institution-id><institution-id institution-id-type="GRID">grid.412166.6</institution-id><institution content-type="org-division">Facultad de Medicina, Evidence Therapeutic Group</institution><institution content-type="org-name">Universidad de La Sabana</institution></institution-wrap><addr-line content-type="street">Campus Universitario, Km 7, Vía La Caro, Autopista Norte</addr-line><addr-line content-type="city">Chía</addr-line><addr-line content-type="state">Cundinamarca</addr-line><country country="CO">Colombia</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2111 4451</institution-id><institution-id institution-id-type="GRID">grid.412166.6</institution-id><institution content-type="org-division">Clinical Pharmacology Department</institution><institution content-type="org-name">Clínica Universidad de La Sabana</institution></institution-wrap><addr-line content-type="city">Chía</addr-line><addr-line content-type="state">Cundinamarca</addr-line><country country="CO">Colombia</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1761 4447</institution-id><institution-id institution-id-type="GRID">grid.412195.a</institution-id><institution content-type="org-division">Bacterial Molecular Genetics Laboratory</institution><institution content-type="org-name">Universidad El Bosque</institution></institution-wrap><addr-line content-type="city">Bogotá DC</addr-line><country country="CO">Colombia</country></aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2111 4451</institution-id><institution-id institution-id-type="GRID">grid.412166.6</institution-id><institution content-type="org-division">Critic Medicine and Intensive Care Resident</institution><institution content-type="org-name">Universidad de La Sabana</institution></institution-wrap><addr-line content-type="city">Chía</addr-line><addr-line content-type="state">Cundinamarca</addr-line><country country="CO">Colombia</country></aff></contrib-group><author-notes><corresp id="IDs1325601920623_cor1"><label>a</label><email>julio.garcia@unisabana.edu.co</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>8</day><month>5</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2019</year></pub-date><volume>13</volume><issue seq="141">1</issue><elocation-id>141</elocation-id><history><date date-type="registration"><day>25</day><month>3</month><year>2019</year></date><date date-type="received"><day>14</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>25</day><month>3</month><year>2019</year></date><date date-type="online"><day>8</day><month>5</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s). 2019</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="url">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" ext-link-type="url">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1" xml:lang="en"><title>Abstract</title><sec id="ASec1"><title>Background</title><p id="Par1">Carbapenem-resistant <italic>Acinetobacter baumannii</italic> infections are a major public health problem worldwide, requiring the use of “old” antibiotics such as polymyxin B and E (colistin). However, there is concern regarding the emergence of isolates resistant to these antibiotics.</p></sec><sec id="ASec2"><title>Case presentation</title><p id="Par2">We report a case of a 64-year-old mestizo man hospitalized in an intensive care unit of a health institution in Colombia with identification and clinical and molecular typing of a colistin- and carbapenem-resistant <italic>A. baumannii</italic> isolate with mechanisms of resistance to colistin not previously reported, causing bacteremia.</p></sec><sec id="ASec3"><title>Conclusions</title><p id="Par3">We have identified a strain of <italic>A. baumannii</italic> with mechanisms of resistance to colistin not previously reported in a patient with bacteremia who required treatment with multiple antibiotic schemes and had an adequate response.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>Acinetobacter baumannii</italic></kwd><kwd>Colistin resistance</kwd><kwd><italic>bla</italic><sub>OXA-23</sub></kwd><kwd>Bacteremia</kwd><kwd>Colombia</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Departamento Administrativo de Ciencia, Tecnología e Innovación (CO)</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">El Bosque University PCI-2014-63 and Administrative Department of Science, Technology and Innovation/Colciencias grant 1308-71250819.</award-id></award-group><award-group><funding-source><institution-wrap><institution>universidad el bosque</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">El Bosque University PCI-2014-63</award-id><principal-award-recipient><name><surname>Escobar-Perez</surname><given-names>Javier</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>BioMed Central</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>No</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>25</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/13256_2019_Article_2062.pdf</meta-value></custom-meta><custom-meta><meta-name>pdf-type</meta-name><meta-value>Typeset</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Medicine &amp; Public Health</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Medicine/Public Health, general</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>General Practice / Family Medicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Public Health</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Primary Care Medicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Surgical Oncology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Internal Medicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Medicine</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">The first global report on antibiotic resistance by the World Health Organization shows carbapenem resistance rates above 40% in <italic>Acinetobacter baumannii</italic>. Additionally, this bacterium is a leading cause of nosocomial infections, especially in intensive care units (ICUs), causing outbreaks with high mortality rates [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. <italic>A. baumannii</italic> has a natural resistance to some classes of antibiotics and an extraordinary ability to acquire resistance to others, including those regarded as last-line antibiotics, such as carbapenems. The most frequent carbapenemases in <italic>A. baumannii</italic> are the class D serine oxacillinases, which mainly belong to OXA-23. OXA-24, OXA-58, and OXA-143-like types begin mobilizing within plasmids or are inserted directly in chromosomes. In Colombia and other Latin American countries, the OXA-23 group-derived carbapenemases are the most prevalent. Carbapenem resistance has led to the need to use “old” antibiotics, such as fosfomycin and polymyxins (B and E). However, the use of these antibiotics has already caused the emergence of resistant isolates. In this scenario, without new antibiotics, the last option is treatment with combination therapies of two or more antibiotics [<xref ref-type="bibr" rid="CR3">3</xref>]. This report describes a case of a patient with bacteremia caused by a pan-resistant <italic>A. baumannii</italic> isolate.</p></sec><sec id="Sec2"><title>Case presentation</title><p id="Par5">On March 11, 2016, a 64-year-old mestizo man with a history of benign prostatic hyperplasia and use of an indwelling catheter presented to our emergency department with urinary retention. Cystoscopy revealed intravesical clots and obstructive bilobar prostate. Following the procedure, the patient exhibited signs of systemic inflammatory response syndrome and pathologic urinalysis. Therefore, antibiotic therapy with ampicillin/sulbactam was initiated without improvement in the clinical features. The urine culture report showed the presence of carbapenem-sensitive <italic>Pseudomonas aeruginosa</italic> and <italic>Enterobacter cloacae</italic>. Therefore, the therapy was subsequently escalated to meropenem (1 g every 8 h). The patient presented with clinical deterioration and ventilatory failure and was referred to the ICU for orotracheal intubation. He also developed cardiopulmonary arrest, which required basic and advanced resuscitation techniques for 11 min with subsequent sinus rhythm. On physical examination, the patient was under sedation, tachycardic, and hypothermic with evidence of purulent urethral discharge, and he required vasopressor support and sedoanalgesia. He had multiple organ dysfunctions due to urinary and pulmonary sepsis with the identification of carbapenem-resistant <italic>Klebsiella pneumoniae</italic> in the blood and lower respiratory tract secretions. The antibiotic therapy was adjusted to colistimethate (90,000 IU/kg) divided into three daily doses, doripenem (1 g every 8 h), and fosfomycin (4 g every 6 h). The patient initially progressed toward improvement, but 72 h later, he presented with new signs of inflammatory response. Therefore, a new blood culture was performed, revealing a carbapenem-resistant <italic>A. baumannii</italic> isolate (minimum inhibitory concentrations [MICs] ≥ 16, ≥ 16, and ≥ 8 μg/ml for imipenem, meropenem, and doripenem, respectively) that was also resistant to gentamicin (MIC ≥ 16 μg/ml), ciprofloxacin (MIC ≥ 4 μg/ml), and colistin (MIC 16 μg/ml) and sensitive only to tigecycline (MIC 1 μg/ml). Following this test, tigecycline administration was initiated (100 mg every 12 h), and colistimethate was suspended, with fosfomycin and doripenem continued until the completion of 14 days of treatment. Nevertheless, due to the persistent systemic inflammatory response on day 10, rifampicin (600 mg/day) and ertapenem (1 g every 12 h) were initiated for pharmacological synergism until day 14. With the prescribed antibiotic therapy, the patient improved in terms of infection, with an absence of fever and decreased leukocyte count. New blood and urine cultures were done, with negative results.</p><p id="Par6">Molecular typing confirmed the genus and species of the isolate as <italic>A. baumannii</italic> (excluding other species of the <italic>Acinetobacter</italic> genus), as well as the presence of the <italic>bla</italic><sub>OXA-23</sub> gene (associated with carbapenem resistance). The isolate belonged to the sequence type (ST) 944, which has also been described in isolates identified in Russia, Italy, and the United States. Studies have identified intrahospital outbreaks of colistin-resistant bacteria with predominant genotype according to multilocus sequence typing was ST-258, ST11, ST273, and ST15 for <italic>K. pneumoniae</italic>; ISAba1 in <italic>P. aeruginosa</italic>, and pmrA1 and pmrB genotype ST94 for <italic>A. baumannii</italic> [<xref ref-type="bibr" rid="CR4">4</xref>]<italic>.</italic> There are few reports on the resistance mechanisms associated with resistance to colistin in <italic>A. baumannii</italic>, the most important one being that related to loss in the production of lipid A of lipopolysaccharide. This loss has been associated with mutations in the <italic>pmrAB</italic> and <italic>lpxACD</italic> operons, <italic>lpxK</italic>, or the <italic>IS</italic>Aba11 insertion [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The sequencing of these two operons in the <italic>A. baumannii</italic> isolate identified two nonsynonymous mutations (H31P and I215M) in the <italic>lpxC</italic> gene from the ATCC 19606 strain and another nonsynonymous mutation (A178G) in the <italic>pmrC</italic> gene from the ATCC 17978 strain [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref>]. None of these mutations has previously been reported in colistin-resistant strains. Although they have been found in the <italic>A. baumannii</italic> isolate, their possible association with resistance should be confirmed experimentally.</p></sec><sec id="Sec3" sec-type="discussion"><title>Discussion</title><p id="Par7"><italic>A. baumannii</italic> infections are a public health problem worldwide because there are fewer and fewer treatment options available. Multidrug-resistant (MDR) <italic>A. baumannii</italic> infection rates of up to 60% and mortality rates of 7% [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] have been reported. One of the possible causes of this resistance is the indiscriminate use of antibiotics such as carbapenems, which are used in monotherapy in patients without comorbidities, resulting in increased resistance [<xref ref-type="bibr" rid="CR12">12</xref>]. In the particular case of <italic>A. baumannii</italic> infection, the treatment options include the combination of carbapenems with tigecycline, aminoglycosides, and polymyxin B and E (colistin) [<xref ref-type="bibr" rid="CR13">13</xref>]. Combination therapy including carbapenems aims for the “suicidal effect of the carbapenem,” and although it has been used in <italic>K. pneumoniae,</italic> it is also a treatment possibility for <italic>A. baumannii</italic> [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par8">Regarding the use of polymyxin B or colistin, the former is usually preferred because its dosage is easier and more effective, the time to achieve optimal serum concentration is faster, there is less variability in pharmacokinetics, and no adjustment is required for renal failure. However, in our patient, the use of colistin was preferred due to the need to cover a pulmonary nidus and the possibility of inhaled administration [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, fosfomycin is a broad-spectrum antibiotic that is especially used in combination therapy because it decreases the MIC of MDR strains and its use in monotherapy induces the development of resistance [<xref ref-type="bibr" rid="CR18">18</xref>]. Currently, the clinical use of tigecycline in MDR infections is under discussion. Some meta-analyses suggest that it should be the treatment of choice in patients with carbapenemase-producing MDR gram-negative bacteria in combination with other classes of antibiotics. Synergism with polymyxins or carbapenems is not as clear as with other antibiotics such as fosfomycin or aminoglycosides [<xref ref-type="bibr" rid="CR17">17</xref>]. Rifampicin was included in our patient’s regimen because this antibiotic, although effective in monotherapy, has a good synergistic activity with other antimicrobials, especially colistin, by permeabilizing the bacterial membrane and increasing the treatment effectiveness [<xref ref-type="bibr" rid="CR19">19</xref>]. Although cefiderocol—a cephalosporin—is not a new class of antibiotic, it has a novel method of penetrating the tough outer membrane of gram-negative bacteria, including MDR strains. Attached to the drug’s main molecule is a siderophore, a compound secreted by bacteria to seek out iron, which bacteria need for survival, and transport it across cell membranes. The results of a phase 2 clinical trial suggest that a new treatment for patients with complicated urinary tract infections caused by MDR pathogens could be on the horizon [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec4" sec-type="conclusions"><title>Conclusions</title><p id="Par9">The emergence of colistin-resistant <italic>A. baumannii</italic> strains in the clinical setting, although still occasional, is increasing due to the growing use of this antibiotic. We have identified a strain of <italic>A. baumannii</italic> with mechanisms of resistance to colistin not previously reported in a patient with bacteremia, required treatment with multiple antibiotic schemes with adequate response. More studies are required to determine other possible genetic mechanisms associated with this resistance in order to develop a better approach to the management of patients with infections caused by this microorganism.</p></sec></body><back><ack><title>Acknowledgements</title><sec><p>We acknowledge the clinical laboratory of Compensar at Clínica Universidad de La Sabana.</p></sec><sec id="FPar1"><title>Funding</title><p id="Par10">This work was financially supported by El Bosque University PCI-2014-63 and Administrative Department of Science, Technology and Innovation/Colciencias grant 1308-71250819.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par11">Data sharing was not applicable to this article, because no datasets were generated or analyzed during the current study.</p></sec></ack><sec sec-type="author-contribution"><title>Authors’ contributions</title><p>JCGC, HRA and AMCM: conception, patient revision, literature review; ZCR and JEP: bacterial molecular analysis, literature review; JCGG, HRA, AMCM, ZCR and JEP: articule review and final publication. All authors read and approved the final manuscript.</p></sec><sec sec-type="ethics-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par12">Approval for publication was obtained from the local ethics committee of Clínica Universidad de La Sabana. A copy of the ethics committee approval is available for review by the Editor-in-Chief of this journal.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par13">Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p></sec><sec id="FPar5" sec-type="COI-statement"><title>Competing interests</title><p id="Par14">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher’s Note</title><p id="Par15">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruppé</surname><given-names>É</given-names></name><name><surname>Woerther</surname><given-names>PL</given-names></name><name><surname>Barbier</surname><given-names>F</given-names></name></person-group><article-title xml:lang="en">Mechanisms of antimicrobial resistance in Gram-negative bacilli</article-title><source>Ann Intensive Care</source><year>2015</year><volume>5</volume><issue>1</issue><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s13613-015-0061-0</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>NM</given-names></name><name><surname>Zhanel</surname><given-names>GG</given-names></name><name><surname>Lynch</surname><given-names>JP</given-names></name></person-group><article-title xml:lang="en">Emergence of antimicrobial resistance among <italic>Acinetobacter</italic> species</article-title><source>Curr Opin Crit Care</source><year>2016</year><volume>22</volume><issue>5</issue><fpage>491</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1097/MCC.0000000000000337</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>GC</given-names></name><name><surname>Oliveira</surname><given-names>MS</given-names></name><name><surname>Perdigioo-Neto</surname><given-names>LV</given-names></name><name><surname>Rocha</surname><given-names>CKD</given-names></name><name><surname>Guimares</surname><given-names>T</given-names></name><name><surname>Rizek</surname><given-names>C</given-names></name><etal/></person-group><article-title xml:lang="en">Antimicrobial combinations against pan-resistant <italic>Acinetobacter baumannii</italic> isolates with different resistance mechanisms</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>3</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0151270</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuita-Gutiérrez</surname><given-names>LF</given-names></name><name><surname>Jiménez</surname><given-names>JN</given-names></name></person-group><article-title xml:lang="en">Brotes hospitalarios de bacterias resistentes a colistina: revisión sistemática de la literatura</article-title><source>Infectio</source><year>2017</year><volume>21</volume><issue>4</issue><fpage>214</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.22354/in.v21i4.684</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>JR</given-names></name><name><surname>Richie</surname><given-names>DL</given-names></name><name><surname>Mostafavi</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>LE</given-names><suffix>4th</suffix></name><name><surname>Rath</surname><given-names>CM</given-names></name><name><surname>Sawyer</surname><given-names>WS</given-names></name><name><surname>Takeoka</surname><given-names>KT</given-names></name><name><surname>Dean</surname><given-names>CR</given-names></name></person-group><article-title xml:lang="en">LpxK is essential for growth of <italic>Acinetobacter baumannii</italic> ATCC 19606: relationship to toxic accumulation of lipid A pathway intermediates</article-title><source>mSphere</source><year>2017</year><volume>2</volume><fpage>e00199</fpage><lpage>e00117</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXhs1SlsbbI</pub-id><pub-id pub-id-type="doi">10.1128/mSphere.00199-17</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffatt</surname><given-names>JH</given-names></name><name><surname>Harper</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>P</given-names></name><name><surname>Hale</surname><given-names>JD</given-names></name><name><surname>Vinogradov</surname><given-names>E</given-names></name><name><surname>Seemann</surname><given-names>T</given-names></name><name><surname>Henry</surname><given-names>R</given-names></name><name><surname>Crane</surname><given-names>B</given-names></name><name><surname>St Michael</surname><given-names>F</given-names></name><name><surname>Cox</surname><given-names>AD</given-names></name><name><surname>Adler</surname><given-names>B</given-names></name><name><surname>Nation</surname><given-names>RL</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Boyce</surname><given-names>JD</given-names></name></person-group><article-title xml:lang="en">Colistin resistance in <italic>Acinetobacter baumannii</italic> is mediated by complete loss of lipopolysaccharide production</article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><fpage>4971</fpage><lpage>4977</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3cXhsF2nu7jO</pub-id><pub-id pub-id-type="doi">10.1128/AAC.00834-10</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Rojas</surname><given-names>R</given-names></name><name><surname>Jiménez-Mejías</surname><given-names>ME</given-names></name><name><surname>Lepe</surname><given-names>JA</given-names></name><name><surname>Pachón</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en"><italic>Acinetobacter baumannii</italic> resistant to colistin alters its antibiotic resistance profile: a case report from Spain</article-title><source>J Infect Dis</source><year>2011</year><volume>204</volume><issue>7</issue><fpage>1147</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir476</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesho</surname><given-names>E</given-names></name><name><surname>Yoon</surname><given-names>EJ</given-names></name><name><surname>McGann</surname><given-names>P</given-names></name><name><surname>Snesrud</surname><given-names>E</given-names></name><name><surname>Kwak</surname><given-names>Y</given-names></name><name><surname>Milillo</surname><given-names>M</given-names></name><name><surname>Onmus-Leone</surname><given-names>F</given-names></name><name><surname>Preston</surname><given-names>L</given-names></name><name><surname>St Clair</surname><given-names>K</given-names></name><name><surname>Nikolich</surname><given-names>M</given-names></name><name><surname>Viscount</surname><given-names>H</given-names></name><name><surname>Wortmann</surname><given-names>G</given-names></name><name><surname>Zapor</surname><given-names>M</given-names></name><name><surname>Grillot-Courvalin</surname><given-names>C</given-names></name><name><surname>Courvalin</surname><given-names>P</given-names></name><name><surname>Clifford</surname><given-names>R</given-names></name><name><surname>Waterman</surname><given-names>PE</given-names></name></person-group><article-title xml:lang="en">Emergence of colistin-resistance in extremely drug-resistant <italic>Acinetobacter baumannii</italic> containing a novel pmrCAB operon during colistin therapy of wound infections</article-title><source>J Infect Dis</source><year>2013</year><volume>208</volume><issue>7</issue><fpage>1142</fpage><lpage>1151</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3sXhvVOis7vI</pub-id><pub-id pub-id-type="doi">10.1093/infdis/jit293</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agodi</surname><given-names>A</given-names></name><name><surname>Voulgari</surname><given-names>E</given-names></name><name><surname>Barchitta</surname><given-names>M</given-names></name><name><surname>Quattrocchi</surname><given-names>A</given-names></name><name><surname>Bellocchi</surname><given-names>P</given-names></name><name><surname>Poulou</surname><given-names>A</given-names></name><name><surname>Santangelo</surname><given-names>C</given-names></name><name><surname>Castiglione</surname><given-names>G</given-names></name><name><surname>Giaquinta</surname><given-names>L</given-names></name><name><surname>Romeo</surname><given-names>MA</given-names></name><name><surname>Vrioni</surname><given-names>G</given-names></name><name><surname>Tsakris</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Spread of a carbapenem- and colistin-resistant <italic>Acinetobacter baumannii</italic> ST2 clonal strain causing outbreaks in two Sicilian hospitals</article-title><source>J Hosp Infect</source><year>2014</year><volume>86</volume><fpage>260</fpage><lpage>266</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BC2crosFKltQ%3D%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.jhin.2014.02.001</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peleg</surname><given-names>AY</given-names></name><name><surname>Seifert</surname><given-names>H</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name></person-group><article-title xml:lang="en"><italic>Acinetobacter baumannii</italic>: emergence of a successful pathogen</article-title><source>Clin Microbiol Rev</source><year>2008</year><volume>21</volume><issue>3</issue><fpage>538</fpage><lpage>582</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD1cXpslajs7Y%3D</pub-id><pub-id pub-id-type="doi">10.1128/CMR.00058-07</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cisneros</surname><given-names>JM</given-names></name><name><surname>Rodríguez-Baño</surname><given-names>J</given-names></name><name><surname>Fernández-Cuenca</surname><given-names>F</given-names></name><name><surname>Ribera</surname><given-names>A</given-names></name><name><surname>Vila</surname><given-names>J</given-names></name><name><surname>Pascual</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">Risk-factors for the acquisition of imipenem-resistant <italic>Acinetobacter baumannii</italic> in Spain: a nationwide study</article-title><source>Clin Microbiol Infect</source><year>2005</year><volume>11</volume><issue>11</issue><fpage>874</fpage><lpage>879</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BD2MrktVOmsw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1111/j.1469-0691.2005.01256.x</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garnacho-Montero</surname><given-names>J</given-names></name><name><surname>Amaya-Villar</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Multiresistant <italic>Acinetobacter baumannii</italic> infections: epidemiology and management</article-title><source>Curr Opin Infect Dis</source><year>2010</year><volume>23</volume><issue>4</issue><fpage>332</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e32833ae38b</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brust</surname><given-names>K</given-names></name><name><surname>Evans</surname><given-names>A</given-names></name><name><surname>Plemmons</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review</article-title><source>J Antimicrob Chemother</source><year>2014</year><volume>69</volume><issue>10</issue><fpage>2606</fpage><lpage>10</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXis1Ciur0%3D</pub-id><pub-id pub-id-type="doi">10.1093/jac/dku189</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulik</surname><given-names>CC</given-names></name><name><surname>Nicolau</surname><given-names>DP</given-names></name></person-group><article-title xml:lang="en">Double-carbapenem therapy for carbapenemase-producing <italic>Klebsiella pneumoniae</italic></article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><issue>6</issue><fpage>3002</fpage><lpage>3004</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXnt1Khs7Y%3D</pub-id><pub-id pub-id-type="doi">10.1128/AAC.01420-10</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheah</surname><given-names>SE</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tsuji</surname><given-names>BT</given-names></name><name><surname>Forrest</surname><given-names>A</given-names></name><name><surname>Bulitta</surname><given-names>JB</given-names></name><name><surname>Nation</surname><given-names>RL</given-names></name></person-group><article-title xml:lang="en">Colistin and polymyxin B dosage regimens against <italic>Acinetobacter baumannii</italic>: differences in 2 activity and the emergence of resistance</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><fpage>3921</fpage><lpage>3933</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XhvFSjtbzO</pub-id><pub-id pub-id-type="doi">10.1128/AAC.02927-15</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigatto</surname><given-names>MH</given-names></name><name><surname>Oliveira</surname><given-names>MS</given-names></name><name><surname>Perdigão-Neto</surname><given-names>LV</given-names></name></person-group><article-title xml:lang="en">Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B</article-title><source>Antimicrob Agents Chemother</source><year>2016</year><volume>60</volume><issue>4</issue><fpage>2443</fpage><lpage>2449</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28Xht1WqtL%2FI</pub-id><pub-id pub-id-type="doi">10.1128/AAC.02634-15</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulakou</surname><given-names>G</given-names></name><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Righi</surname><given-names>E</given-names></name><name><surname>Dimopoulos</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens</article-title><source>Future Microbiol</source><year>2014</year><volume>9</volume><fpage>1053</fpage><lpage>1069</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXhsl2msb7K</pub-id><pub-id pub-id-type="doi">10.2217/fmb.14.58</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>SL</given-names></name><name><surname>Frantzeskaki</surname><given-names>F</given-names></name><name><surname>Wallis</surname><given-names>SC</given-names></name><name><surname>Diakaki</surname><given-names>C</given-names></name><name><surname>Giamarellou</surname><given-names>H</given-names></name><name><surname>Koulenti</surname><given-names>D</given-names></name><etal/></person-group><article-title xml:lang="en">Population pharmacokinetics of fosfomycin in critically ill patients</article-title><source>Antimicrob Agents Chemother</source><year>2015</year><volume>59</volume><issue>10</issue><fpage>6471</fpage><lpage>6476</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28Xht1yju7o%3D</pub-id><pub-id pub-id-type="doi">10.1128/AAC.01321-15</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nastro</surname><given-names>M</given-names></name><name><surname>Rodríguez</surname><given-names>CH</given-names></name><name><surname>Monge</surname><given-names>R</given-names></name><name><surname>Zintgraff</surname><given-names>J</given-names></name><name><surname>Neira</surname><given-names>L</given-names></name><name><surname>Rebollo</surname><given-names>M</given-names></name><etal/></person-group><article-title xml:lang="en">Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria</article-title><source>J Chemother</source><year>2014</year><volume>26</volume><issue>4</issue><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2cXhtVGqtbvO</pub-id><pub-id pub-id-type="doi">10.1179/1973947813Y.0000000136</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portsmouth</surname><given-names>S</given-names></name><name><surname>Veenhuyzen</surname><given-names>D</given-names></name><name><surname>Echols</surname><given-names>R</given-names></name><name><surname>Machida</surname><given-names>M</given-names></name><name><surname>Arjona</surname><given-names>JC</given-names></name></person-group><article-title xml:lang="en">Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial</article-title><source>Lancet Infect Dis</source><year>2018</year><volume>18</volume><issue>12</issue><fpage>1319</fpage><lpage>1328</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXitVWqu77J</pub-id><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30554-1</pub-id></mixed-citation></ref></ref-list></ref-list></back></article></records><facets><facet name="subject"><facet-value count="1">General Practice / Family Medicine</facet-value><facet-value count="1">Internal Medicine</facet-value><facet-value count="1">Medicine &amp; Public Health</facet-value><facet-value count="1">Medicine/Public Health, general</facet-value><facet-value count="1">Primary Care Medicine</facet-value><facet-value count="1">Public Health</facet-value><facet-value count="1">Surgical Oncology</facet-value></facet><facet name="keyword"><facet-value count="1">
                Acinetobacter baumannii
              </facet-value><facet-value count="1">
                bla
                OXA-23
              </facet-value><facet-value count="1">Bacteremia</facet-value><facet-value count="1">Colistin resistance</facet-value><facet-value count="1">Colombia</facet-value></facet><facet name="pub"><facet-value count="1">Journal of Medical Case Reports</facet-value></facet><facet name="year"><facet-value count="1">2019</facet-value></facet><facet name="country"><facet-value count="1">Colombia</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
